Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic Analysis launches GA-map test for infants

This article was originally published in Clinica

Executive Summary

Norwegian molecular diagnostics specialist Genetic Analysis has launched its GA-map test for analysing gut microbes in infants. It is now available worldwide for research use only. GA-map works on the principle that many disorders could be linked to an imbalance in the gut microbial profile, including inflammatory bowel disease, allergy, autism and obesity. The product can process more than 200 samples per day, the Aas-based company claims. GA-map could increase understanding of the causes of disease by highlighting differences in microbial profiles between patients and healthy controls. "Looking ahead, the technology could be used to develop intelligent treatments based on personalised medicine," said the firm's CEO, Dr Morten Isaksen. Genetic Analysis is also developing an adult version of the test.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel